Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $8.72, but opened at $8.36. Sysmex shares last traded at $8.37, with a volume of 3,981 shares traded.
Analysts Set New Price Targets
Separately, Citigroup downgraded shares of Sysmex from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 16th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold".
View Our Latest Analysis on SSMXY
Sysmex Price Performance
The company's 50-day moving average price is $8.82 and its 200-day moving average price is $9.59. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44. The company has a market cap of $5.29 billion, a P/E ratio of 17.52 and a beta of 1.10.
Sysmex (OTCMKTS:SSMXY - Get Free Report) last announced its earnings results on Thursday, February 12th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. The business had revenue of $837.32 million during the quarter, compared to analysts' expectations of $819.99 million. As a group, sell-side analysts predict that Sysmex Corporation ADR will post 0.44 earnings per share for the current fiscal year.
About Sysmex
(
Get Free Report)
Sysmex Corporation OTCMKTS: SSMXY is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex's product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.
The company's core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sysmex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.
While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.